Cereblon binding molecules in multiple myeloma

Blood Reviews

Volumn 29, Issue 5, 2015, Pages 329-334

  Kortum K M ^a   Zhu, Y X ^a   Shi, C X ^a   Jedlowski, P ^a   Stewart, A K ^a  

^a MAYO CLINIC   (United States)

Author keywords

Aiolos; Cereblon; Cereblon binding molecules; Ikaros; IMiDs; Lenalidomide; Multiple myeloma; Pomalidomide; Thalidomide

Indexed keywords

ANTHRACYCLINE; BORTEZOMIB; CARFILZOMIB; CEREBLON BINDING MOLECULE; DEXAMETHASONE; IMMUNOMODULATING AGENT; LENALIDOMIDE; POMALIDOMIDE; THALIDOMIDE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; CRBN PROTEIN, HUMAN; PEPTIDE HYDROLASE;

AMINO ACID SUBSTITUTION; ANGIOGENESIS; ANTI MYELOMA ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER RESISTANCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CONTACT; CELL PROLIFERATION; CRBN GENE; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG ACTIVITY; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG STRUCTURE; GENE; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNOMODULATION; MULTIPLE MYELOMA; OVERALL SURVIVAL; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; GENETICS; METABOLISM;

HUMANS; MULTIPLE MYELOMA; PEPTIDE HYDROLASES;

EID: 84941259096     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2015.03.003     Document Type: Article

References (114)

1. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341:1565-1571.
2. Ito T., Ando H., Suzuki T., Ogura T., Hotta K., Imamura Y., et al. Identification of a primary target of thalidomide teratogenicity. Science 2010, 327:1345-1350.
3. Egan J.B., Kortuem K.M., Kurdoglu A., Izatt T., Aldrich J., Reiman R., et al. Extramedullary myeloma whole genome sequencing reveals novel mutations in cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease. Br J Haematol 2013, 161:748-751.
4. Zhu Y.X., Braggio E., Shi C.X., Bruins L.A., Schmidt J.E., Van Wier S., et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011, 118:4771-4779.
5. Lopez-Girona A., Mendy D., Ito T., Miller K., Gandhi A.K., Kang J., et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012, 26:2326-2335.
6. Broyl A., Kuiper R., van Duin M. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 2013, 121:624-627.
7. Heintel D., Rocci A., Ludwig H., Bolomsky A., Caltagirone S., Schreder M., et al. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol 2013, 161:695-700.
8. Schuster S.R., Kortuem K.M., Zhu Y.X., Braggio E., Shi C.X., Bruins L.A., et al. The clinical significance of cereblon expression in multiple myeloma. Leuk Res 2014, 38:23-28.
9. Huang S.Y., Lin C.W., Lin H.H., Yao M., Tang J.L., Wu S.J., et al. Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Ann Hematol 2014, 93:1371-1380.
10. Kronke J., Udeshi N.D., Narla A., Grauman P., Hurst S.N., McConkey M., et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014, 343:301-305.
11. Zhu Y.X., Braggio E., Shi C.X., Kortuem K.M., Bruins L.A., Schmidt J.E., et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood 2014, 124:536-545.
12. Kortuem K.M., Zidich K., Schuster S.R., Khan M.L., Jimenez-Zepeda V.H., Mikhael J.R., et al. Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma. Clin Lymphoma Myeloma Leuk 2014, 14:284-290.
13. Chamberlain P.P., Lopez-Girona A., Miller K., Carmel G., Pagarigan B., Chie-Leon B., et al. Structure of the human cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol 2014, 21:803-809.
14. Fischer E.S., Bohm K., Lydeard J.R., Yang H., Stadler M.B., Cavadini S., et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 2014, 512:49-53.
15. Lu G., Middleton R.E., Sun H., Naniong M., Ott C.J., Mitsiades C.S., et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014, 343:305-309.
16. Laubach J.P., Schlossman R.L., Mitsiades C.S., Anderson K.C., Richardson P.G. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Rev Hematol 2011, 4:51-60.
17. Lacy M.Q., Tefferi A. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update. Leuk Lymphoma 2011, 52:560-566.
18. Vacca A., Ria R., Reale A., Ribatti D. Angiogenesis in multiple myeloma. Chem Immunol Allergy 2014, 99:180-196.
19. Kumar S., Witzig T.E., Dispenzieri A., Lacy M.Q., Wellik L.E., Fonseca R., et al. Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia 2004, 18:624-627.
20. Corral L.G., Haslett P.A., Muller G.W., Chen R., Wong L.M., Ocampo C.J., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999, 163:380-386.
21. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991, 173:699-703.
22. Maiga S., Gomez-Bougie P., Bonnaud S., Gratas C., Moreau P., Le Gouill S., et al. Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma. Br J Cancer 2013, 108:1801-1806.
23. Payvandi F., Wu L., Haley M., Schafer P.H., Zhang L.H., Chen R.S., et al. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol 2004, 230:81-88.
24. Keller M., Sollberger G., Beer H.D. Thalidomide inhibits activation of caspase-1. J Immunol 2009, 183:5593-5599.
25. Teo S., Resztak K.E., Scheffler M.A., Kook K.A., Zeldis J.B., Stirling D.I., et al. Thalidomide in the treatment of leprosy. Microbes Infect 2002, 4:1193-1202.
26. Starkey C.R., Joste N.E., Lee F.C. Near-total resolution of multicentric Castleman disease by prolonged treatment with thalidomide. Am J Hematol 2006, 81:303-304.
27. Thalidomide Gutierrez-Rodriguez O. A promising new treatment for rheumatoid arthritis. Arthritis Rheum 1984, 27:1118-1121.
28. Atra E., Sato E.I. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 1993, 11:487-493.
29. Kari J.A., Shah V., Dillon M.J. Behcet's disease in UK children: clinical features and treatment including thalidomide. Rheumatology (Oxford) 2001, 40:933-938.
30. Hideshima T., Mitsiades C., Tonon G., Richardson P.G., Anderson K.C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007, 7:585-598.
31. Bjorklund C.C., Ma W., Wang Z.Q., Davis R.E., Kuhn D.J., Kornblau S.M., et al. Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem 2011, 286:11009-11020.
32. Bjorklund C.C., Baladandayuthapani V., Lin H.Y., Jones R.J., Kuiatse I., Wang H., et al. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia 2014, 28:373-383.
33. Breitkreutz I., Raab M.S., Vallet S., Hideshima T., Raje N., Mitsiades C., et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008, 22:1925-1932.
34. Hideshima T., Anderson K.C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002, 2:927-937.
35. Geitz H., Handt S., Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996, 31:213-221.
36. Guirgis A.A., Zahran M.A., Mohamed A.S., Talaat R.M., Abdou B.Y., Agwa H.S. Effect of thalidomide dithiocarbamate analogs on the intercellular adhesion molecule-1 expression. Int Immunopharmacol 2010, 10:806-811.
37. Teoh G., Anderson K.C. Interaction of tumor and host cells with adhesion and extracellular matrix molecules in the development of multiple myeloma. Hematol Oncol Clin North Am 1997, 11:27-42.
38. Martiniani R., Di Loreto V., Di Sano C., Lombardo A., Liberati A.M. Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma. Adv Hematol 2012, 2012:842945.
39. Settles B., Stevenson A., Wilson K., Mack C., Ezell T., Davis M.F., et al. Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide. Cell Mol Biol (Noisy-le-Grand) 2001, 47:1105-1114.
40. Lin Y.C., Shun C.T., Wu M.S., Chen C.C. A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clin Cancer Res 2006, 12:7165-7173.
41. Oliveira A.M., Maria D.A., Metzger M., Linardi C., Giorgi R.R., Moura F., et al. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients. Leuk Res 2009, 33:970-973.
42. Azab A.K., Runnels J.M., Pitsillides C., Moreau A.S., Azab F., Leleu X., et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009, 113:4341-4351.
43. Liu P., Li J., Lu H., Xu B. Thalidomide inhibits leukemia cell invasion and migration by upregulation of early growth response gene 1. Leuk Lymphoma 2009, 50:109-113.
44. Nogueira A.C., Neubert R., Helge H., Neubert D. Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sci 1994, 55:77-92.
45. Lentzsch S., Gries M., Janz M., Bargou R., Dorken B., Mapara M.Y. Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003, 101:3568-3573.
46. Terpos E., Dimopoulos M.A., Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007, 21:1875-1884.
47. Bolzoni M., Storti P., Bonomini S., Todoerti K., Guasco D., Toscani D., et al. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. Exp Hematol 2013, 41:387-397.
48. Escoubet-Lozach L., Lin I.L., Jensen-Pergakes K., Brady H.A., Gandhi A.K., Schafer P.H., et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009, 69:7347-7356.
49. Gandhi A.K., Kang J., Capone L., Parton A., Wu L., Zhang L.H., et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010, 10:155-167.
50. Verhelle D., Corral L.G., Wong K., Mueller J.H., Moutouh-de Parseval L., Jensen-Pergakes K., et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007, 67:746-755.
51. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Richardson P.G., Hideshima T., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99:4525-4530.
52. Shalapour S., Zelmer A., Pfau M., Moderegger E., Costa-Blechschmidt C., van Landeghem F.K., et al. The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo. Clin Cancer Res 2006, 12:5526-5532.
53. Gockel H.R., Lugering A., Heidemann J., Schmidt M., Domschke W., Kucharzik T., et al. Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway. J Immunol 2004, 172:5103-5109.
54. Chauhan D., Hideshima T., Anderson K.C. Apoptotic signaling in multiple myeloma: therapeutic implications. Int J Hematol 2003, 78:114-120.
55. Chu Z.L., McKinsey T.A., Liu L., Gentry J.J., Malim M.H., Ballard D.W. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc Natl Acad Sci U S A 1997, 94:10057-10062.
56. Kreuz S., Siegmund D., Scheurich P., Wajant H. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol 2001, 21:3964-3973.
57. Bataille R., Robillard N., Avet-Loiseau H., Harousseau J.L., Moreau P. CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity. Haematologica 2005, 90:706-707.
58. Sprynski A.C., Hose D., Caillot L., Reme T., Shaughnessy J.D., Barlogie B., et al. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 2009, 113:4614-4626.
59. Chan A.C., Neeson P., Leeansyah E., Tainton K., Quach H., Prince H.M., et al. Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy. Clin Exp Immunol 2014, 175:49-58.
60. Pratt G., Goodyear O., Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007, 138:563-579.
61. Prabhala R.H., Neri P., Bae J.E., Tassone P., Shammas M.A., Allam C.K., et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006, 107:301-304.
62. Busch A., Zeh D., Janzen V., Mugge L.O., Wolf D., Fingerhut L., et al. Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients. Clin Exp Immunol 2014, 177:439-453.
63. Mozaffari F., Hansson L., Kiaii S., Ju X., Rossmann E.D., Rabbani H., et al. Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage. Br J Haematol 2004, 124:315-324.
64. Li S., Pal R., Monaghan S.A., Schafer P., Ouyang H., Mapara M., et al. IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood 2011, 117:5157-5165.
65. Quach H., Ritchie D., Stewart A.K., Neeson P., Harrison S., Smyth M.J., et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010, 24:22-32.
66. Luptakova K., Rosenblatt J., Glotzbecker B., Mills H., Stroopinsky D., Kufe T., et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother 2013, 62:39-49.
67. Ratta M., Fagnoni F., Curti A., Vescovini R., Sansoni P., Oliviero B., et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002, 100:230-237.
68. Nair J.R., Carlson L.M., Koorella C., Rozanski C.H., Byrne G.E., Bergsagel P.L., et al. CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment. J Immunol 2011, 187:1243-1253.
69. Okunishi K., Dohi M., Nakagome K., Tanaka R., Mizuno S., Matsumoto K., et al. A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function. J Immunol 2005, 175:4745-4753.
70. Henry J.Y., Labarthe M.C., Meyer B., Dasgupta P., Dalgleish A.G., Galustian C. Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs(R) immunomodulatory compounds lenalidomide and pomalidomide. Immunology 2013, 139:377-385.
71. Chang D.H., Liu N., Klimek V., Hassoun H., Mazumder A., Nimer S.D., et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006, 108:618-621.
72. Wu L., Adams M., Carter T., Chen R., Muller G., Stirling D., et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008, 14:4650-4657.
73. Hayashi T., Hideshima T., Akiyama M., Podar K., Yasui H., Raje N., et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005, 128:192-203.
74. Davies F.E., Raje N., Hideshima T., Lentzsch S., Young G., Tai Y.T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98:210-216.
75. Ramsay A.G., Clear A.J., Kelly G., Fatah R., Matthews J., Macdougall F., et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009, 114:4713-4720.
76. Ramsay A.G., Johnson A.J., Lee A.M., Gorgun G., Le Dieu R., Blum W., et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008, 118:2427-2437.
77. Gorgun G., Ramsay A.G., Holderried T.A., Zahrieh D., Le Dieu R., Liu F., et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci U S A 2009, 106:6250-6255.
78. Aue G., Njuguna N., Tian X., Soto S., Hughes T., Vire B., et al. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 2009, 94:1266-1273.
79. Quintana F.J., Jin H., Burns E.J., Nadeau M., Yeste A., Kumar D., et al. Aiolos promotes TH17 differentiation by directly silencing Il2 expression. Nat Immunol 2012, 13:770-777.
80. Schafer P.H., Gandhi A.K., Loveland M.A., Chen R.S., Man H.W., Schnetkamp P.P., et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003, 305:1222-1232.
81. Haslett P.A., Corral L.G., Albert M., Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998, 187:1885-1892.
82. LeBlanc R., Hideshima T., Catley L.P., Shringarpure R., Burger R., Mitsiades N., et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004, 103:1787-1790.
83. De Keersmaecker B., Fostier K., Corthals J., Wilgenhof S., Heirman C., Aerts J.L., et al. Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation. Cancer Immunol Immunother 2014, 63:1023-1036.
84. Lan R.Y., Ansari A.A., Lian Z.X., Gershwin M.E. Regulatory T cells: development, function and role in autoimmunity. Autoimmun Rev 2005, 4:351-363.
85. Feyler S., Selby P.J., Cook G. Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM). Blood Rev 2013, 27:155-164.
86. Feyler S., von Lilienfeld-Toal M., Jarmin S., Marles L., Rawstron A., Ashcroft A.J., et al. CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol 2009, 144:686-695.
87. Beyer M., Kochanek M., Giese T., Endl E., Weihrauch M.R., Knolle P.A., et al. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 2006, 107:3940-3949.
88. Giannopoulos K., Schmitt M., Wlasiuk P., Chen J., Bojarska-Junak A., Kowal M., et al. The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia 2008, 22:222-224.
89. Minnema M.C., van der Veer M.S., Aarts T., Emmelot M., Mutis T., Lokhorst H.M. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia 2009, 23:605-607.
90. Raja K.R., Plasil M., Rihova L., Pelcova J., Adam Z., Hajek R. Flow cytometry-based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment. Cytometry B Clin Cytom 2014, 86:220-228.
91. Jones E., Dahm-Vicker M., Simon A.K., Green A., Powrie F., Cerundolo V., et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2002, 2:1.
92. Galustian C., Meyer B., Labarthe M.C., Dredge K., Klaschka D., Henry J., et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009, 58:1033-1045.
93. Gorgun G.T., Whitehill G., Anderson J.L., Hideshima T., Maguire C., Laubach J., et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 2013, 121:2975-2987.
94. Richardson P.G., Weller E., Lonial S., Jakubowiak A.J., Jagannath S., Raje N.S., et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116:679-686.
95. Kumar S., Flinn I., Richardson P.G., Hari P., Callander N., Noga S.J., et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012, 119:4375-4382.
96. Wang M., Martin T., Bensinger W., Alsina M., Siegel D.S., Kavalerchik E., et al. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood 2013, 122:3122-3128.
97. Jakubowiak A.J., Dytfeld D., Griffith K.A., Lebovic D., Vesole D.H., Jagannath S., et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 2012, 120:1801-1809.
98. Mikhael J.R., Reeder C.B., Libby E.N., Costa L.J., Bergsagel P.L., Buadi F., et al. Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma. Br J Haematol 2015 Feb 13, 10.1111/bjh.13296.
99. Stewart A.K., Rajkumar S.V., Dimopoulos M.A., Masszi T., Špička I., Oriol A., et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015, 372:142-152.
100. Kortuem K.M., Stewart A.K. Carfilzomib. Blood 2013, 121:893-897.
101. Leleu X., Rodon P., Hulin C., Daley L., Dauriac C., Hacini M., et al. MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. Thromb Haemost 2013, 110:844-851.
102. Palumbo A., Bringhen S., Kumar S.K., Lupparelli G., Usmani S., Waage A., et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol 2014, 15:333-342.
103. Baz R., Patel M., Finley-Oliver E., Lebovic D., Hussein M.A., Miller K.C., et al. Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis. Leuk Lymphoma 2010, 51:1015-1019.
104. Rajkumar S.V., Gertz M.A., Lacy M.Q., Dispenzieri A., Fonseca R., Geyer S.M., et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003, 17:775-779.
105. Ocio E.M., Fernandez-Lazaro D., San-Segundo L., Lopez-Corral L., Corchete L.A., Gutierrez N.C., et al. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia 2014, 10.1038/leu.2014.238.
106. Lohr J.G., Stojanov P., Carter S.L., Cruz-Gordillo P., Lawrence M.S., Auclair D., et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014, 25:91-101.
107. Bolli N., Avet-Loiseau H., Wedge D.C., Van Loo P., Alexandrov L.B., Martincorena I., et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 2014, 5:2997.
108. Thakurta A., Gandhi A.K., Waldman M.F., Bjorklund C., Ning Y., Mendy D., et al. Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. Leukemia 2014, 28:1129-1131.
109. Lacy M.Q., Allred J.B., Gertz M.A., Hayman S.R., Short K.D., Buadi F., et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011, 118:2970-2975.
110. Leleu X., Attal M., Arnulf B., Moreau P., Traulle C., Marit G., et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02. Blood 2013, 121:1968-1975.
111. Offidani M., Corvatta L., Caraffa P., Leoni P., Pautasso C., Larocca A., et al. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data. Expert Rev Anticancer Ther 2014, 14:499-510.
112. Richardson P.G., Siegel D.S., Vij R., Hofmeister C.C., Baz R., Jagannath S., et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 2014, 123:1826-1832.
113. Lacy M.Q., Hayman S.R., Gertz M.A., Short K.D., Dispenzieri A., Kumar S., et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010, 24:1934-1939.
114. McCurdy A.R., Lacy M.Q. Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist. Ther Adv Hematol 2013, 4:211-216.